journal article·2023-12Open access

Distinct Conformations of Mirabegron Determined by MicroED

Jieye Lin, Johan Unge, Tamir Gonen

Advanced Science· Volume 10· Issue 34

Abstract

Abstract Mirabegron, commonly known as “Myrbetriq”, has been widely prescribed as a medicine for overactive bladder syndrome for over a decade. However, the structure of the drug and what conformational changes it may undergo upon binding its receptor remain unknown. In this study, the authors employed microcrystal electron diffraction (MicroED) to reveal its elusive three‐dimensional (3D) structure. They find that the drug adopts two distinct conformational states (conformers) within the asymmetric unit. Analysis of hydrogen bonding and packing demonstrated that the hydrophilic groups are embedded within the crystal lattice, resulting in a hydrophobic surface and low water solubility. Structural comparison revealed the presence of trans ‐ and cis ‐ forms in conformers 1 and 2 , respectively. Comparison of the structures of Mirabegron alone with that of the drug bound to its receptor, the beta 3 adrenergic receptor (β3AR) suggests that the drug undergoes major conformational change to fit in the receptor agonist binding site. This research highlights the efficacy of MicroED in determining the unknown and polymorphic structures of active pharmaceutical ingredients (APIs) directly from powders.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Urinary Tract Infections Management · Spectroscopy and Quantum Chemical Studies · Molecular spectroscopy and chirality

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Chemistry University of California 615 Charles E. Young Drive South Los Angeles CA 90095 USA

Department of Physiology University of California 615 Charles E. Young Drive South Los Angeles CA 90095 USA

Howard Hughes Medical Institute University of California Los Angeles CA 90095 USA

Funding

National Institutes of Health · Howard Hughes Medical Institute

References (33)

Show source-provided references
1. 10.1016/j.molcel.2021.06.02410.1016/j.molcel.2021.06.024 ↗
2. 10.1517/17460441.2014.89292310.1517/17460441.2014.892923 ↗
3. 10.1124/jpet.106.11584010.1124/jpet.106.115840 ↗
4. 10.1111/ijcp.1243310.1111/ijcp.12433 ↗
5. 10.1073/pnas.190165511610.1073/pnas.1901655116 ↗
6. 10.3390/pharmaceutics1003014910.3390/pharmaceutics10030149 ↗
7. 10.1097/01.NPR.0000425824.44694.e810.1097/01.NPR.0000425824.44694.e8 ↗
8. Kane S. · ClinCalc DrugStats Database · 2020 · 20
9. 10.1017/S088571561700112910.1017/S0885715617001129 ↗
10. Tamayo A. P. · Rev. Invest. Univ. Quindío. · 2019 · 31
11. 10.1007/978-1-4939-7000-1_1010.1007/978-1-4939-7000-1_10 ↗
12. 10.1021/ja00501a00910.1021/ja00501a009 ↗
13. 10.7554/eLife.0134510.7554/eLife.01345 ↗
14. 10.1038/nmeth.304310.1038/nmeth.3043 ↗
15. 10.1039/C7CC03180G10.1039/C7CC03180G ↗
16. 10.1002/anie.20181131810.1002/anie.201811318 ↗
17. 10.1002/anie.20190456410.1002/anie.201904564 ↗
18. 10.1021/jacs.1c0172910.1021/jacs.1c01729 ↗
19. 10.1002/anie.20230376110.1002/anie.202303761 ↗
20. 10.1039/D1RA03100G10.1039/D1RA03100G ↗
21. 10.1002/anie.20211498510.1002/anie.202114985 ↗
22. 10.1038/s42004-022-00804-210.1038/s42004-022-00804-2 ↗
23. 10.1039/D2CE01522F10.1039/D2CE01522F ↗
24. 10.1021/acs.cgd.3c0043210.1021/acs.cgd.3c00432 ↗
25. Burch J. E. · ChemRxiv · 2021
26. 10.1021/acscentsci.8b0076010.1021/acscentsci.8b00760 ↗
27. 10.1107/S205225251901058310.1107/S2052252519010583 ↗
28. 10.1107/S090744490904733710.1107/S0907444909047337 ↗
29. 10.1107/S090744490904737410.1107/S0907444909047374 ↗
30. 10.1107/S205327331402637010.1107/S2053273314026370 ↗
31. 10.1107/S205322961402421810.1107/S2053229614024218 ↗
32. 10.1007/b13561810.1007/b135618 ↗
33. 10.1016/S0022-2860(98)00806-010.1016/S0022-2860(98)00806-0 ↗